← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,162	+3	+0.3%	$66.3B
2	2 Danaher DHR $158B	1,117	-12	-1%	$46.1B
3	3 Novartis NVS $279B	938	+17	+2%	$22.2B
4	4 Agilent Technologies A $49.1B	620	+31	+5%	$17.6B
5	5 Regeneron Pharmaceuticals REGN $80.1B	606	+2	+0.3%	$32.3B
6	6 Illumina ILMN $41B	576	+12	+2%	$26.9B
7	7 Revvity RVTY $17B	350	+10	+3%	$7.02B
8	8 Charles River Laboratories CRL $14.4B	336	+34	+11%	$4.96B
9	9 Ionis Pharmaceuticals IONS $7.1B	301	+7	+2%	$5.84B
10	10 DELISTED CATALENT, INC. CTLT	286	+45	+19%	$5.33B
11	11 DELISTED bluebird bio BLUE	243	+2	+0.8%	$6.9B
12	12 Alnylam Pharmaceuticals ALNY $30B	236	+9	+4%	$10.3B
13	13 Sarepta Therapeutics SRPT $1.78B	233	+43	+23%	$2.44B
14	14 Myriad Genetics MYGN $397M	220	-19	-8%	$2.72B
15	15 Azenta AZTA $1.63B	217	-5	-2%	$1.96B
16	16 Qiagen QGEN $9.41B	215	+4	+2%	$4.49B
17	17 Bruker BRKR $8.47B	201	+1	+0.5%	$3.1B
18	18 Precigen PGEN $2.64B	155	-17	-10%	$1.78B
19	19 Ultragenyx Pharmaceutical RARE $1.47B	154	-5	-3%	$2.16B
20	20 DELISTED SANGAMO THERAPEUTICS INC SGMO	148	+5	+3%	$820M
21	21 PTC Therapeutics PTCT $4.98B	129	+15	+13%	$715M
22	22 Editas Medicine EDIT $349M	116	+6	+5%	$698M
23	SIOX 23 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	114	+1	+0.9%	$718M
24	24 Lineage Cell Therapeutics LCTX $232M	102	-7	-6%	$140M
25	25 Pacific Biosciences PACB $619M	98	-9	-8%	$430M